<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04338477</url>
  </required_header>
  <id_info>
    <org_study_id>920174</org_study_id>
    <nct_id>NCT04338477</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety and Efficacy of Nephrosolid Tbs to Stimulate Urinary Output in Non-patient Volunteers</brief_title>
  <official_title>Multizentrische, Offene Studie Zur Beurteilung Der Vertr√§glichkeit Und Wirksamkeit Von Nephrosolid Tabletten Zur Anregung Der Harnausscheidung Bei Probanden/Non-patient Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioforce AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioforce AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fluid intake and urinary output are measured with /without intake of Nephrosolid tablets in
      acute ( 1 day application ) and chronic ( 28 days application) therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate safety and efficacy of Nephrosolid tbs in the stimulation of urinary output in
      healthy volunteers, all participants in this open-label study will be asked to record their
      fluid intake and output on day 0 (without study medication), on day 1 (with 3 x 2 tablets
      study medication, to be taken 1/2 hour before meals) and on day 28 (with 2 x 1 tablets study
      medication, morning and noon half an hour before meals) and to take 2 x 1 tablet of
      Nephrosolid on days 2-28. Subjects will complete a diary during the study to record the
      tablets taken, amount of fluid consumed, weight, physical activity, and urinary measurement.
      Safety labs (hematology, clinical chemistry) will be performed at each study visit on days -1
      and 29.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Actual">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 17, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability as assessed by the treating physician</measure>
    <time_frame>day 29</time_frame>
    <description>Tolerability is assessed at 2nd visit /study end, after 4 weeks of intake, according to four step scale ( poor, moderate, good, very good)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Urine Specimen Collection</condition>
  <arm_group>
    <arm_group_label>Nephrosolid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute dosis day 1: 3X2 Nephrosolid tablets 0.5 h before intake of a meal Long-term dosis days 2-28: 2x1 Nephrosolid tablets 0.5 h before intake of a meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nephrosolid tablets</intervention_name>
    <description>Adminstration of drug</description>
    <arm_group_label>Nephrosolid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willingness and ability to record urine volume and fluid consumption over 3 days.

          -  Written consent to participate in the study.

        Exclusion Criteria:

          -  Disease or comprehension problems (language) that affect the accurate collection and
             measurement of urine levels over 3 days.

          -  Taking diuretic drugs, teas, herbal supplements, or systemic corticosteroids.

          -  Chronic nephropathy (such as glomerulonephritis, analgesic nephropathy, interstitial
             nephritis).

          -  Pregnancy or lactation.

          -  Psychiatric disorders that include suicidality.

          -  Surgical intervention in the 3 months prior to enrollment or scheduled surgery during
             the study.

          -  Known chronic diseases such as dementia, progressive systemic diseases.

          -  Known alcohol and/or drug addiction.

          -  Known allergies to goldenrod or birch leaves.

          -  Participation in one or more other clinical trials in the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernhard Waelti, Dr. med.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Privat practice of Dr. med. Bruno Haug, Medizinisches Zentrum Arbon</name>
      <address>
        <city>Arbon</city>
        <state>Thurgau</state>
        <zip>9320</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice Dr. med Bernhard Waelti</name>
      <address>
        <city>Freidorf</city>
        <state>Thurgau</state>
        <zip>9306</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 4, 2018</study_first_submitted>
  <study_first_submitted_qc>April 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

